CWBR — CohBar Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Cohbar Announces Acceptance Of Late Breaking Abstract On Its Antifibrotic Peptides
Brief: CohBar Posts Quarterly Loss Per Share Of $0.09
NASDAQ RESUMED AT 10:18 AM
NASDAQ RESUMED AT 10:12 AM
NASDAQ RESUMED AT 10:07 AM
NASDAQ RESUMED AT 10:00 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:48 AM
Brief: Cohbar Reports Third Quarter 2019 Financial Results
Brief: Cohbar Completes Phase 1A And Initiates Phase 1B Stage Of Clinical Trial Of Cb4211 Under Development For Nash And Obesity
Brief: Cohbar Q2 Loss Per Share $0.07
Brief: Cohbar Inc - Preclinical Results Showing Efficacy Of A New Family Of Mitochondria Based Therapeutics In A Type 2 Diabetes Model
U.S. STOCKS ON THE MOVE-Cruise stocks, bank stocks, chipmakers
Brief: Cohbar Q1 Loss Per Share $0.07
Brief: CohBar Appoints Steven Engle As CEO
Brief: Cohbar To Resume Its Phase 1A/1B Clinical Trial
Brief: Cohbar Says Board Increased Number Of Its Directors To Eight - SEC Filing
Brief: Cohbar Q4 Loss Per Share $0.10
Brief: Cohbar Inc Says On Feb 8, Board Increased Number Of Its Directors To 7
Brief: Cohbar Appoints Philippe Calais As Interim CEO